Underwood, M. (Martin) M.D., Ashby, Deborah, Carnes, Dawn, Castelnuovo, E. (Emanuela), Cross, Pamela, Harding, Geoff, Hennessy, Enid M., Letley, Louise, Martin, Jeannett, Mt-Isa, Shahrul, Parsons, Suzanne, Spencer, A., Vickers, Madge and Whyte, Ken. (2008) Topical or oral ibuprofen for chronic knee pain in older people : the TOIB study. Health Technology Assessment, Vol.12 (No.22). ISSN 1366-5278

Preview	Text WRAP_Underwood_Topical_oral_ibuprofen.pdf - Published Version Download (1423Kb) | Preview
Preview	Text (Coversheet) WRAP_coversheet_Underwood_Topical_oral_ibuprofen.pdf - Supplemental Material Download (51Kb) | Preview

Abstract

Objectives: To determine whether GPs should advise their older patients with chronic knee pain to use topical or oral non-steroidal anti-inflammatory drugs (NSAIDs). Design: An equivalence study was designed to compare the effect of advice to use preferentially oral or topical ibuprofen (an NSAID) on knee pain and disability, NSAID-related adverse effects and NHS/societal costs, using a randomised controlled trial (RCT) and a patient preference study (PPS). Reasons for patient preferences for topical or oral preparations, and attitudes to adverse effects, were explored in a qualitative study. Setting: Twenty-six general practices in the UK. Participants: Participants comprised 585 people with knee pain, aged 50 years or over; 44% were male, mean age 64 years. The RCT had 282 participants: 144 in the oral group and 138 in the topical group. The PPS had 303 participants: 79 in the oral group and 224 in the topical group. Interventions: Advice to use preferentially oral or topical NSAIDs for knee pain. Outcome measures: The primary outcome measure was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcome measures were the Short Form with 36 Items (SF-36), perceived troublesomeness of knee pain, satisfaction with health status, major adverse effects (unplanned hospital admissions and deaths) and minor adverse events over 12 months. The health economic analysis measured the comparative cost per quality-adjusted life-year (QALY) from both an NHS and a societal perspective over 1 and 2 years. Results: Changes in the global WOMAC score at 12-months were equivalent in both studies: topical – oral, RCT difference = 2 [95% confidence interval (CI) –2 to 6], PPS difference = 1 (95% CI –4 to 6). There were no differences in the secondary outcomes, except for a suggestion, in the RCT, that those in the topical group were more likely to have more severe overall pain and disability as measured by the chronic pain grade, and more likely to report changing treatment because of inadequate pain relief. There were no differences in the rate of major adverse effects but some differences in the number of minor ones. In the RCT, 17% and 10% in the oral and the topical group, respectively, had a defined respiratory adverse effect (95% CI of difference –17% to –2.0%); after 12 months, the change in serum creatinine was 3.7 mmol/l (95% CI 0.9 to 6.5) less favourable in the oral than in the topical group, and 11% of those in the oral group reported changing treatment because of adverse effects compared with 1% in the topical group (p = 0.02). None of these differences were seen in the PPS. Oral NSAIDs cost the NHS £191 and £72 more per participant over 1 year in the RCT and PPS respectively. In the RCT the cost per QALY in the oral group, from an NHS perspective, was in the range £9000–12,000. In the PPS it was £2564 over 1 year, but over 2 years the oral route was more cost-effective. Patient preference for medication type was affected by previous experience of medication (including adverse reactions), other illness, pain elsewhere, anecdotes, convenience, severity of pain and perceived degree of degeneration. Lack of understanding about knee pain and the action of medication led to increased tolerance of symptoms. Potentially important symptoms may inadvertently have been disregarded, increasing participants' risk of suffering a major adverse effect. Conclusions: Advice to use either oral or topical preparations has an equivalent effect on knee pain, but oral NSAIDs appear to produce more minor adverse effects than topical NSAIDs. Generally, these results support advising older people with knee pain to use topical rather than oral NSAIDS. However, for patients who prefer oral NSAID preparations rather than a topical NSAID, particularly those with more widespread or severe pain, the oral route is a reasonable treatment option, provided that patients are aware of the risks of potentially serious adverse effects from oral medication. Further research is needed into strategies to change prescribing behaviour and ensure that older patients are aware of the potential risks and benefits of using NSAIDs. Observational studies are needed to estimate rates of different predefined minor adverse effects associated with the use of oral NSAIDs in older people as are long-term studies of topical NSAIDs in those for whom oral NSAIDs are not appropriate.

Item Type:	Journal Article
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Nonsteroidal anti-inflammatory agents, Knee -- Wounds and injuries -- Treatment, Knee -- Diseases -- Treatment, Patient satisfaction, Ibuprofen, Chronic pain -- Treatment
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	May 2008
Volume:	Vol.12
Number:	No.22
Number of Pages:	176
Identification Number:	10.3310/hta12220
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Gabriel SE. Update on the epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1996;8:96–100. 2. Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain interference in a general population of older adults: crosssectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004;110: 361–8. 3. Urwin M, Symmons D, Allison T, Brammah T, Busby H, Roxby M, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis 1998;57:649–55. 4. O’Reilly SC, Muir KR, Doherty M. Screening for pain in knee osteoarthritis: which question? Ann Rheum Dis 1996;55:931–3. 5. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002;100: 55–64. 6. Jinks C, Jordan K, Ong BN, Croft P. A brief screening tool for knee pain in primary care (KNEST). 2 Results from a survey in the general population aged 50 or over. Rheumatology (Oxford). 2004;43:55–61. 7. Bedson J, Jordan K, Croft P. Chronic knee pain and osteoarthritis: an epidemiological study of labels, diagnosis and investigation in general practice. Fam Pract 2005;22:103–8. 8. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49. 9. Sharma L, Kapoor D, Issa S. Epidemiology of osteoarthritis: an update. Curr Opin Rheumatol 2006;18:147–56. 10. Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical classification criteria for knee osteoarthritis: performance in the general population and primary care. Ann Rheum Dis 2006;65:1363–7. 11. Brooks P, Hochberg M. Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups. Rheumatology (Oxford) 2001;40:896–906. 12. Underwood MR. Community management of knee pain in older people: is knee pain the new back pain? Rheumatology (Oxford) 2004; 42:1–2. 13. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905–15. 14. Jawad AS. Analgesics and osteoarthritis: are treatment guidelines reflected in clinical practice? Am J Ther 2005;12:98–103. 15. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317. 16. Chard J, Lohmander S, Smith C, Scott D. Osteoarthritis of the knee. Clin Evid 2005;1506–22. 17. Dieppe PA, Cushnaghan J, Jasani MK, McCrea F, Watt I. A two-year, placebo-controlled trial of non steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993;32:595–600. 18. Scott DL, Berry H, Capell H, Coppock J, Daymond T, Doyle DV, et al. The long term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomised placebocontrolled trial. Rheumatology (Oxford) 2000;39: 1095–101. 19. Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196–206. 20. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795–808. 21. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81. 22. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665–74. 23. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal antiinflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti- Inflammatory Drug Guideline Development Group. BMJ 1998;317:526–30. 24. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004;63:1028–34. 25. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587–98. 26. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004;51:746–54. 27. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;(1):CD004257. 28. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000;43:378–85. 29. OA Nation. Arthritis care. URL: http://oanation. arthritiscare.org.ukfileadmin/oanation/downloads/ OA_Nation_report.pdf. Accessed 23 June 2006. 30. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000;27:1020–7. 31. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931–9. 32. Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563–6. 33. Peura DA, Goldkind L. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005;7 Suppl 4:S7–13. 34. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000;60:555–74. 35. Cooper C, Jordan KM. Topical NSAIDs in osteoarthritis. BMJ 2004;329:304–5. 36. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324. 37. Arthritis Research Campaign. Arthritis. The big picture. www.arc.org.uk/arthinfo/bigpic.asp. Accessed 23 February 2008. 38. Phillips AC, Polisson RP, Simon LS. NSAIDs and the elderly. Toxicity and economic implications. Drugs Aging 1997;10:119–30. 39. Langman MJ. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf 2001;10:13–19. 40. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and metaanalysis. BMC Musculoskeletal Disord 2004;5:28. 41. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997;26:755–70. 42. Towheed TE. Published meta-analyses of pharmacological therapies for osteoarthritis. Osteoarthritis Cartilage 2002;10:836–7. 43. British National Formulary. 52nd ed. London: BMJ, Royal Pharmaceutical Society of Great Britain; 2006. 44. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11: 283–91. 45. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–9. 46. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ 2005;331:1310–16. 47. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85: 169–82. 48. Field TS, Gurwitz JH, Glynn RJ, Salive ME, Gaziano JM, Taylor JO, et al. The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc 1999;47:507–11. 49. Kleinknecht D, Landais P, Goldfarb B. Analgesic and non-steroidal anti-inflammatory drug associated acute renal failure: a prospective collaborative study. Clin Nephrol 1986;25:275–81. 50. Whelton A, Hamilton C. Non steroidal antiinflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588–98. 51. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289–300. 52. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434. 53. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase- 2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302–8. 54. Ray W, Stein M, Daugherty J, Hall K, Arbogast P, Griffin M. COX-2 selective non-steroidal antiinflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071–3. 55. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361: 573–4. 56. Rolf C, Engstrom B, Beauchard C, Jacobs LD, Le Liboux A. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999;38:564–7. 57. Dominkus M, Nicolakis M, Kotz R, Wilkinson FE, Kaiser RR, Chlud K. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996;46: 1138–43. 58. Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33:567–73. 59. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 1998;56:783–99. 60. Arcury TA, Gesler WM, Cook HL. Meaning in the use of unconventional arthritis therapies. Am J Health Promot 1999;14:7–15. 61. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328:991. 62. Michalsen A, Klotz S, Ludtke R, Moebus S, Spahn G, Dobos GJ. Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 2003;139:724–30. 63. Knuesel O, Weber M, Suter A. Arnica montana gel in osteoarthritis of the knee: an open, multicenter clinical trial. Adv Ther 2002;19:209–17. 64. Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003;30:523–8. 65. Kimmey MB. NSAID, ulcers, and prostaglandins. J Rheumatol 1992;19(Suppl 36):68–73. 66. O’Callaghan CA, Andrews PA, Ogg CS. Renal disease and use of topical non-steroidal antiinflammatory drugs. BMJ 1994;308:110–11. 67. Fraenkel L, Wittink DR, Concato J, Fried T. Informed choice and the widespread use of antiinflammatory drugs. Arthritis Rheum 2004;51:210–14. 68. Moore R, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999;2:45–55. 69. Bandolier. Topical analgesics: a review of reviews and a bit of perspective. URL: www.ebandolier.com. Bandolier Extra – Evidencebased health care. Accessed March 2005. 70. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000;(2):CD000142. 71. Underwood MR. Is it safe for general practitioners to continue to use ibuprofen for older people with musculoskeletal pain? Rheumatology (Oxford) 2003; 42 (Suppl 1):18. 72. Powell C. The Delphi technique: myths and realities. J Adv Nurs 2003;41:376–82. 73. Laine L. The gastrointestinal effects of nonselective NSAIDs and Cox-2-selective inhibitors. Arthritis Rheum 2002;32 (Suppl 1):25–32. 74. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002;97(8):1951–8. 75. Wroblewski M, Ostberg H. Ulcer disease among geriatric patients with positive faecal occult blood test and/or iron deficiency anaemia. A prospective study. Scand J Gastroenterol 1990;25:489–95. 76. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32 (3 Suppl 1): 33–42. 77. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003;14: 240–6. 78. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An underrecognized public health problem. Arch Intern Med 2000;160:777–84. 79. Whelton A. Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106: 13s–24s. 80. Szczeklik A, Nizankowska E, Mastalerz L, Szabo Z. Analgesics and asthma. Am J Ther 2002;9: 233–43. 81. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717–22. 82. Picardo C. Mechanisms of aspirin sensitivity. Cur Allergy Asthma Rep 2006;6:198–202. 83. Cabral D, Katz JN, Weinblatt M, Ting G, Avom J, Soloman DH. Development and assessment of indicators of rheumatoid arthritis severity: results of a Dephi panel. Arthritis Rheum 2005;53:61–6. 84. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2000;59:936–44. 85. Mitchell HL, Carr AJ, Scott DL. The management of knee pain in primary care: factors associated with consulting the GP and referrals to secondary care. Rheumatology (Oxford) 2006;45:771–6. 86. Hinman R, Crossley K, McConnell J, Bennell K. Efficacy of knee tape in the management of osteoarthritis of the knee: blinded randomised controlled trial. BMJ 2003;327:135. 87. Butler CC, Rollnick S, Pill R, Maggs-Rapport F, Stott N. Understanding the culture of prescribing: qualitative study of general practitioners’ and patients’ perceptions of antibiotics for sore throats. BMJ 1998;317:637–42. 88. Gannik D, Jespersen M. Lay person concepts and strategies for handling symptoms of disease: a sample of adult male and female experience of back pain symptoms. Scand J Primary Health Care 1984;2:67–76. 89. Harding G, Parsons S, Rahman A, Underwood M. “It struck me that they didn’t understand pain”: the specialist pain clinic experience of patients with chronic musculoskeletal pain. Arthritis Rheum 2005;53:691–6. 90. Ross MM, Carswell A, Hing M, Hollingworth G, Dalziel WB. Seniors’ decision making about pain management. J Adv Nurs 2001;35:442–51. 91. Torgerson D, Sibbald B. Understanding controlled trials: what is a patient preference trial? BMJ 1998;7128:360. 92. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ 1989;299:313–15. 93. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials. Health Technol Assess 2005;9(35). 94. MRC. Medical Research Council General Practice Research Framework. http://www.gprf.mrc.ac.uk. Accessed 22 February 2008. 95. Jarman B. Identification of underprivileged areas. Br Med J (Clin Res Ed) 1983;286:1705–9. 96. Jarman B. Underprivileged areas: validation and distribution of scores. Br Med J (Clin Res Ed) 1984;289(6458):1587–92. 97. Bedson J, Mottram S, Thomas E, Peat G. Knee pain and osteoarthritis in the general population: what influences patients to consult? Fam Pract 2007;24:443–53. 98. Data Protection Act 1998. URL: http://www.opsi.gov.uk/ACTS/acts 1998/19980029. htm. Accessed 31 October 2007. 99. European Union. Directive 2001/20/EC – ‘Clinical Trials Directive’. Brussels: European Union; 2001. 100. Neal RD, Heywood PL, Morley S. Real world data – retrieval and validation of consultation data from four general practices. Fam Pract 1996;13:455–61. 101. Jinks C, Lewis M, Ong BN, Croft P. A brief screening tool for knee pain in primary care. 1. Validity and reliability. Rheumatology (Oxford) 2001;40:528–36. 102. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997;17:277–89. 103. Lynfield YL, Schechter S. Choosing and using a vehicle. J Am Acad Dermatol 1984;10:56–9. 104. Azurdia RM, Pagliaro JA, Diffey BL, Rhodes LE. Sunscreen application by photosensitive patients is inadequate for protection. Br J Dermatol 1999;140: 255–8. 105. Finlay A, Edwards P, Harding K. Finger tip unit in dermatology. Lancet 1989;ii:155. 106. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40. 107. Bellamy N. WOMAC Osteoarthritis Index. User Guide, Version V. Brisbane, Australia; 2002. 108. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799–802. 109. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celexicob vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247–55. 110. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–8. 111. Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2:169–80. 112. EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199–208. 113. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133–49. 114. Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, et al. The Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain 1997;71:141–7. 115. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306: 1440–4. 116. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln, RI: Quality Metric; 2000. 117. Parsons S, Carnes D, Pincus T, Foster N, Breen A, Vogel S, et al. Measuring troublesomeness of chronic pain by location. BMC Musculoskel Disord 2006;7:34. 118. Cherkin DC, Deyo RA, Street JH, Barlow W. Predicting poor outcomes for back pain seen in primary care using patients’ own criteria. Spine 1996;21:2900–7. 119. Underwood MR, Morton V, Farrin A, on behalf of the UK BEAM trial team. Baseline characteristics predict response to treatment for low back pain? Secondary analysis of the UK BEAM dataset [ISRCTN32683578]. Rheumatology (Oxford) 2007; 46:1297–302. 120. Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;27:764–71. 121. Cross PL, Ashby D, Harding G, Hennessy EM, Letley L, Parsons S, et al. TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. [ISRCTN79353052]. BMC Musculoskelet Disord 2005;6:55. 122. Drummond MF, O’Brien B, Stoddart GL, Torrence G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997. 123. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40. 124. HM Treasury. The green book: appraisal and evaluation in central government. London: Stationery Office; 2003. 125. Curtis L, Netten A. Unit costs of health and social care. Canterbury: University of Canterbury; 2005. 126. Department of Health. NHS reference costs database for 2005. London: Department of Health; 2005. 127. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21). 128. NICE. Clinical guideline N.3. Preoperative tests. The use of routine preoperative tests for elective surgery. London: National Institute for Health and Clinical Excellence; 2003. 129. Marsh F, Kremer C, Duffy S. Delivering an effective outpatient service in gynaecology. A randomised controlled trial analysing the cost of outpatient versus daycase hysteroscopy. BJOG 2004;111:243–8. 130. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQOL of life: results from a general UK general population survey. Discussion Paper 138. Oxford: Centre for Health Economics; 1995. 131. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med 2005;24:131–45. 132. Raftery J. Review of NICE’s recommendations, 1999–2005. BMJ 2006;332:1266–8. 133. Charles C, Gafni A, Whelan T. Decision-making in the physician–patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999;49:651–61. 134. Thom D, Kravitz R, Bell R, Krupat E, Azari R. Patient trust in the physician: relationship to patient requests. Fam Pract 2002;19:476–83. 135. Awad MA, Shapiro SH LJ, Feine JS. Determinants of patients’ treatment preferences in a clinical trial. Community Dent Oral Epidemiol 2000;28:119–25. 136. Borders T, Rohrer J, Xu T, Smith D. Older persons’ evaluation of health care: the effects of medical scepticism and worry about health. Health Serv Res 2004;39:35–52. 137. Clark JP, Hudak PL, Hawker GA, Coyte PC, Mahomed NN, Kreder HJ, et al. The moving target: a qualitative study of elderly patients’ decision-making regarding total joint replacement surgery. J Bone Joint Surg Am 2004;86-A(7): 1366–74. 138. Goodacre L, Goodacre J. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease modifying medication. Rheumatology (Oxford) 2004;43:583–6. 139. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford) 2002;41:253–61. 140. Sale J, Gignac M, Hawker G. How “bad” does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis. Arthritis Rheum 2006;55:272–8. 141. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61:133–55. 142. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In Bryman A, Burgess RG, editors. Analysing qualitative data. London: Routledge; 1994. pp. 173–94. 143. Stead M, Eadie D, Gordon D, Angus K. “Hello, hello – it’s English I speak!”: a qualitative exploration of patient understanding of the science of clinical trials. J Med Ethics 2005;31: 664–9. 144. Townsend A, Hunt K, Wyke S. Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use. BMJ 2003;327:837. 145. Victor C, Ross F, Axford J. Capturing lay perspective in a randomised control trial of a health promotion intervention for people with osteoarthritis of the knee. J Eval Clin Pract 2004;10:63–70. 146. Herve C, Mullet E, Sorum PC. Age and medication acceptance. Exp Aging Res 2004;30: 253–73. 147. Williams B, Shaw A, Durrant R, Crinson I, Pagliari C, de Lusignan S. Patient perspectives on multiple medication versus combined pills: a qualitative study. Qual J Med 2005;98:885–93. 148. Benson J, Britten N. What effects do patients feel from their antihypertensive tablets and how do they react to them? Qualitative analysis of interviews with patients. Fam Pract 2006;23:80–7. 149. Spinewine A, Swine C, Dhillon S, Franklin B, Tulkens P, Wilmotte L, et al. Appropriateness of use of medicines in elderly inpatients: qualitative study. BMJ 2005;331:935–8. 150. Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manage Care Pharm 2005;11:550–8. 151. Praught ML, Shlipak MG. Are small changes in serum creatinine an important risk factor? Curr Opin Nephrol Hypertens 2005;14:265–70. 152. Shlipak MG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK, et al. Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 2004;43:37–44. 153. Segal L, Day SE, Chapman B, Osborne RH. Can we reduce disease burden from osteoarthritis? Med J Aust 2003;180(Suppl 5):s11–s17. 154. Nicolaides K, Brizot ML, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10–13 weeks’ gestation. Lancet 1994;344:435–9. 155. Ashok PW, Hamoda H, Flett GM, Kidd A, Fitzmaurice A, Templeton A. Patient preference in a randomized study comparing medical and surgical abortion at 10–13 weeks gestation. Contraception 2005;71:143–8. 156. Olschewski M, Schumacher M, Davis KB. Analysis of randomized and nonrandomized patients in clinical trials using the comprehensive cohort follow-up study design. Control Clin Trials 1992;13:226–39. 157. Rabenda V, Burlet N, Raeman F, Belaiche J, Reginster J-Y. A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2005;64:688–93. 158. Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001;28:932–4. 159. Hay E, Foster N, Peat G, Phelan M, Yates H, Bleckinsopp A, et al. Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomised trial. BMJ 2006;333:995. 160. van der Waal JM, Terwee CB, Dekker J. Healthrelated and overall quality of life of patients with chronic hip and knee complaints in general practice. Qual Life Res 2005;14:795–803. 161. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, for the CONSORT group. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. JAMA 2006;295:1152–160.
URI:	http://wrap.warwick.ac.uk/id/eprint/37495

Request changes to a record

Actions (login required)

View Item